Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > AVTX Avalo Therapeutics > Detailed Quotes

AVTX Avalo Therapeutics

4.110
-0.035-0.84%
Trading Session 10/07 14:03 ET
High
4.219
Open
4.182
Turnover
42.20K
Low
4.100
Pre Close
4.145
Volume
10.21K
Market Cap
38.69M
P/E(TTM)
Loss
52wk High
29.400
Shares
9.41M
P/E(Static)
Loss
52wk Low
2.423
Float Cap
13.58M
Bid/Ask %
0.00%
Historical High
91.799
Shs Float
3.30M
Volume Ratio
2.38
Historical Low
2.412
Dividend TTM
--
Div Yield TTM
--
P/B
-6.50
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.31%
Amplitude
2.86%
Avg Price
4.134
Lot Size
1
Float Cap
13.58M
Bid/Ask %
0.00%
Historical High
91.799
Shs Float
3.30M
Volume Ratio
2.38
Historical Low
2.412
Dividend TTM
--
P/B
-6.50
Dividend LFY
--
Turnover Ratio
0.31%
Amplitude
2.86%
Avg Price
4.134
Lot Size
1
Price Forecast

No Data

News

Comment

No More
Company Overview More
Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
CEO: Dr. Garry A. Neil, M.D.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...